GENMAB A/S/S (OTCMKTS:GMXAY – Get Free Report)’s share price rose 3.3% during mid-day trading on Friday . The stock traded as high as $31.8450 and last traded at $31.82. Approximately 1,947,116 shares were traded during mid-day trading, an increase of 3,910% from the average daily volume of 48,553 shares. The stock had previously closed at $30.80.
GENMAB A/S/S Price Performance
The stock’s 50-day simple moving average is $31.29 and its two-hundred day simple moving average is $27.54.
About GENMAB A/S/S
Genmab A/S is a Denmark-based biotechnology company specializing in the creation and development of proprietary antibody therapeutics for the treatment of cancer and autoimmune diseases. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has focused on leveraging its innovative antibody platforms—such as DuoBody, HexaBody and DuoHexaBody—to generate next-generation therapies. The company’s expertise extends from early discovery through preclinical development, after which it partners with larger biopharmaceutical firms to advance candidates through clinical trials and commercialization.
Among Genmab’s most notable products is daratumumab, marketed under the brand name DARZALEX in collaboration with Janssen, which has become a leading monoclonal antibody for the treatment of multiple myeloma.
Featured Articles
- Five stocks we like better than GENMAB A/S/S
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- Do not delete, read immediately
- Ticker Revealed: Pre-IPO Access to “Next Elon Musk” Company
- First Time Since 2007: All Warnings Active
- Best $19 you’ll spend this year.
Receive News & Ratings for GENMAB A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENMAB A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.
